文献速递脑血管病

脑钠肽与卒中后心房颤动的发现:Find-AFRANDOMISED 试验亚组分析

Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AFRANDOMISED Trial.
PubMed 文献 · Stroke · 2019-12-09

本研究为前瞻性随机多中心试验的亚组分析,纳入≥60岁急性脑缺血、窦性心律且无房颤史患者398例,比较增强延长Holter监测与常规诊疗对阵发性房颤的检出率,并评估脑钠肽(BNP)的预测价值。结果显示BNP在房颤患者中更高,以100 pg/mL为界可将需筛查人数从18降至3。

要点

  • BNP在急性卒中后早期升高可识别房颤高危患者。
  • BNP≥100 pg/mL时,增强Holter监测的需筛查人数降至3。
  • 增强Holter监测较常规诊疗显著提高阵发性房颤检出率。

核心结论

  • 急性缺血性卒中后早期测量的BNP可识别房颤风险增高的患者亚组,该亚组中增强延长Holter监测尤为有效。

研究设计与样本

  • 前瞻性随机多中心研究纳入≥60岁急性脑缺血、窦性心律且无房颤史患者,随机接受增强延长Holter监测(3次10天)或常规卒中诊疗,共分析398例。

主要发现

  • 增强延长Holter监测组检出阵发性房颤27例,常规诊疗组检出9例(P=0.002)。
  • 基线时房颤患者中位BNP在增强监测组为57.8 pg/mL vs 无房颤28.3 pg/mL(P=0.0003),对照组为46.2 vs 27.7 pg/mL(P=0.28)。
  • 3个月时房颤患者中位BNP在增强监测组为74.9 vs 31.3 pg/mL(P=0.012),对照组为99.3 vs 26.3 pg/mL(P=0.02)。

关键数值与推荐

  • 以BNP 100 pg/mL为界,需筛查人数从常规诊疗的18降至增强延长Holter监测的3。

临床怎么用

  • 对≥60岁急性缺血性卒中、窦性心律且无房颤史患者,可早期检测BNP,以BNP≥100 pg/mL筛选适合增强延长Holter监测的高危患者。

局限性

  • BNP仅在93.7%患者基线测量、69.1%患者3个月时测量,存在缺失数据。
  • 对照组中房颤与无房颤患者基线BNP差异无统计学意义(P=0.28)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Diagnosing paroxysmal atrial fibrillation (pAF) can be challenging after acute ischemic stroke. Enhanced and prolonged Holter-ECG monitoring (EPM) improves the detection rate but is not feasible for all patients. We hypothesized that brain natriuretic peptide (BNP) may help to identify patients with stroke at high risk for pAF to select patients for EPM more effectively. Methods- Patients with acute cerebral ischemia ≥60 years presenting in sinus rhythm and without history of AF were included into a prospective, randomized multicenter study to receive either EPM (3× 10-day Holter-ECG) or usual stroke care diagnostic work-up. BNP plasma levels were measured on randomization and 3 months thereafter. Levels were compared between patients with and without pAF detected by means of EPM or usual care. Furthermore, the number needed to screen for EPM depending on BNP cut offs was calculated. Results- A total of 398 patients were analyzed. In 373 patients (93.7%), BNP was measured at baseline and in 275 patients (69.1%) after 3 months. pAF was found in 27 patients by means of EPM and in 9 patients by means of usual care (P=0.002). Median BNP was higher in patients with pAF as compared to patients without AF in both study arms at baseline (57.8 versus 28.3 pg/mL in the EPM arm, P=0.0003; 46.2 versus 27.7 pg/mL, P=0.28 in the control arm) and after 3 months (74.9 versus 31.3 pg/mL, P=0.012 in the EPM arm, 99.3 versus 26.3 pg/mL, P=0.02 in the control arm). Applying a cut off of 100 pg/mL, the number needed to screen was reduced from 18 by usual care to 3 by EPM. Conclusions- BNP measured early after ischemic stroke identifies a subgroup of patients with stroke at increased risk for AF, in whom EPM is particularly efficacious. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01855035.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wasser K, Weber-Krüger M, Gröschel S, et al. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AFRANDOMISED Trial. Stroke. 2019. PMID: 31813354. doi:10.1161/STROKEAHA.119.026496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。